Skip to main content

Table 3 Prevalence of most dispensed chronic medications in men (n = 351) and women (n = 1329) centenarians. Drugs are listed in descending order of total prevalence, and only those with prevalence equal to or greater than 1% are represented

From: Health of Spanish centenarians: a cross-sectional study based on electronic health records

ATCa code Chronic medication Men (%) Women (%) P value
A02B Drugs for peptic ulcer and GERDb 53.9 50.2 n.s.c
B01A Antithrombotic agents 43.6 39.9 n.s.
N02B Other analgesics and antipyretics 34.1 36.4 n.s.
C03C High-ceiling diuretics 31.5 34.9 n.s.
N05B Anxiolytics 13.9 23.4 <0.001
N06A Antidepressants 12.8 14.7 n.s.
N05C Hypnotics and sedatives 9.9 14.7 <0.05
N05A Antipsychotics 11.4 14.2 n.s.
C09A ACEd inhibitors, plain 7.3 14.9 <0.001
B03A Iron preparations 12.8 10.7 n.s.
C08C Selective calcium channel blockers with mainly vascular effects 13.9 10.3 n.s.
C05C Capillary stabilizing agents 4.4 11.4 <0.05
C01D Vasodilators used in cardiac diseases 8.1 10.3 n.s.
C09C Angiotensin II receptor blockers, plain 7.0 9.0 n.s.
M02A Topical products for joint and muscular pain 6.1 9.0 n.s.
C09D Angiotensin II receptor blockers, combinations 5.9 8.4 n.s.
S01E Antiglaucoma preparations and miotics 7.7 7.3 n.s.
A06A drugs for constipation 8.1 6.7 n.s.
M01A Antiinflammatory and antirheumatic products, non-steroids 10.3 6.1 <0.05
C01A Cardiac glycosides 8.1 6.6 n.s.
N06B Psychostimulants, agents used for ADHDe and nootropics 8.8 6.0 n.s.
R05C Expectorants, excl. Combinations with cough suppressants 8.4 5.5 n.s.
A10B Blood glucose lowering drugs, excl. Insulins 5.1 5.9 n.s.
V06X General nutrients 5.5 5.6 n.s.
B03B Vitamin B12 and folic acid 5.1 5.5 n.s.
C07A Beta blocking agents 4.4 5.7 n.s.
N02A Opioids 2.2 6.2 <0.05
G04C Drugs used in benign prostatic hypertrophy 26.0 0.0 <0.001
C10A Lipid modifying agents, plain 6.6 4.3 n.s.
C04A Peripheral vasodilators 5.5 4.1 n.s.
R03A Adrenergics, inhalants 7.3 3.7 <0.05
R03B Other drugs for obstructive airway diseases, inhalants 7.3 3.7 <0.05
S01X Other ophthalmologicals 3.7 4.4 n.s.
C09B ACE inhibitors, combinations 3.7 4.3 n.s.
D01A Antifungals for topical use 4.0 4.2 n.s.
C03D Potassium-sparing agents 5.9 3.6 n.s.
C03E Diuretics and potassium-sparing agents in combination 1.1 4.6 <0.05
A03F Propulsives 1.1 4.1 <0.05
R06A Antihistamines for systemic use 5.5 3.1 n.s.
C01E Other cardiac preparations 3.7 3.4 n.s.
C03B Low-ceiling diuretics, excl. Thiazides 2.6 3.6 n.s.
C08D Selective calcium channel blockers with direct cardiac effects 3.7 2.7 n.s.
A12A Calcium 0.7 3.3 <0.05
A12B Potassium 1.8 3.1 n.s.
D07A Corticosteroids, plain 4.8 2.3 <0.05
M04A Antigout preparations 5.9 2.0 <0.001
N03A Antiepileptics 1.8 3.0 n.s.
N07C Antivertigo preparations 2.9 2.6 n.s.
J01 M Quinolone antibacterials 4.0 1.9 n.s.
H02A Corticosteroids for systemic use, plain 3.7 1.7 n.s.
H03A Thyroid preparations 1.1 2.3 n.s.
J01X Other antibacterials 2.9 1.4 n.s.
J01C Beta-lactam antibacterials, penicillins 2.6 1.4 n.s.
N06D Anti-dementia drugs 1.8 1.6 n.s.
V06Z General nutrients 2.9 1.4 n.s.
S01A Antiinfectives 0.7 1.7 n.s.
A10A Insulins and analogues 1.5 1.4 n.s.
C03A Low-ceiling diuretics, thiazides 0.7 1.4 n.s.
J01D Other beta-lactam antibacterials 1.1 1.4 n.s.
R05D Cough suppressants, excl. Combinations with expectorants 2.3 1.0 n.s.
H03B Antithyroid preparations 0.7 1.1 n.s.
  1. aAnatomical Therapeutic Chemical Classification System; bGastroesophageal reflux disease; cNot statistically significant; dAngiotensin-converting-enzyme; eAttention deficit hyperactivity disorder